Extended Data Fig. 4: TAMs in human GBM after neoadjuvant anti-PD-1 therapy evaluated by scRNA-seq. | Nature Cancer

Extended Data Fig. 4: TAMs in human GBM after neoadjuvant anti-PD-1 therapy evaluated by scRNA-seq.

From: Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response

Extended Data Fig. 4

(a and b) Proportions of microglia (C1) (a) and CXCL10+ microglia (C8) (b) across ND (n = 5), Rec (n = 7), nonresponder (n = 5) and responder (n = 7) tumor samples. Data are presented as the mean ± SEM. Two-sided fisher’s exact test. n.s., not significant. (c) Comparison of the average expression of each gene in CXCL10+ microglia (C8) (y-axis) versus microglia (C1) (x-axis). Red points indicate selected significantly upregulated genes in CXCL10+ microglia (C8) with an adjusted P < 0.01 (One-sided wilcoxon rank-sum test). (d) Boxplot showing the ROUGE index of each subset across 24 patients. (e) The developmental trajectory of all monocytes, macrophages and microglia inferred by RNA velocity analysis. Arrows indicate the orientation of the inferred developmental pseudotime trajectory. UMAP plot showing individual cell cluster. Heatmap showing smoothened expression of selected genes in SIGLEC9+SEPP1+ TAMs (C2), SIGLEC9+MARCO+ TAMs (C9) and CD14+ monocytes (C3). The columns represent individual genes and are aligned along the pseudotime trajectory. (f) Volcano plot showing differentially expressed genes of SIGLEC9+SEPP1+ TAMs (C2) in Rec vs ND groups. (g) Violin plot showing selected genes in published dataset.

Source data

Back to article page